Inovio (Nasdaq:INO) announced today that it appointed Dr. Michael Sumner as its new chief medical officer (CMO).
Sumner will oversee Inovio’s clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, along with regulatory affairs, pharmacovigilance and medical affairs.
He will also serve on the company’s executive leadership team and report to President and CEO Dr. Jacqueline Shea in his role at the Plymouth Meeting, Pennsylvania-based developer of vaccines and vaccine delivery technology.
Get the full story at our sister site, Drug Delivery Business News.